Media October 2, 2023: Interview of Hervé Affagard – La Bourse et La Vie TV (French only) MaaT PharmaOctober 3, 2023
Media September 23, 2023: BFM Business interview of Hervé Affagard – Check-up Santé (French only) MaaT PharmaSeptember 25, 2023
Media September 19, 2023: Le Point – Traitement des cancers : le microbiote intestinal passe en phase industrielle (French only) MaaT PharmaSeptember 22, 2023
Media September 13, 2023: Endpoints News – MaaT Pharma and CDMO Skyepharma unveil bespoke, and potentially largest, microbiome facility in Europe MaaT PharmaSeptember 22, 2023
Media July 7, 2023: France 2- Les pouvoirs extraordinaires du corps humain (French only) The Extraordinary Powers of the Human Body Stomachaches, Depression, Cancer: The Microbiota RevolutionMaaT PharmaJuly 7, 2023
Media April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013 MaaT PharmaMay 3, 2023
Media April 28, 2023: Microbiome Post – MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease MaaT PharmaMay 3, 2023
Media April 25, 2023: BioPharma Reporter – FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic MaaT PharmaMay 3, 2023
Media April 24, 2023 : Endpoints News – FDA lifts nearly two-year hold on MaaT Pharma’s microbiome therapy, opens door to PhIII MaaT PharmaMay 3, 2023
Media April 24, 2023: The Pharma Letter – FDA lifts clinical hold of MaaT Pharma’s lead microbiome therapeutic trial MaaT PharmaMay 3, 2023
